Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Just rewatched the redchip presentation (thanks Mike).. blows my mind...
It's crazy that a lot of the penny stocks on Ihub have 6-700 boardmarks, and we have less than 50..
36 boardmarks now,... we were sitting at 19-20 for over a year, almost doubled in a couple months.
Things are starting to heat up.. fireworks this week?
Mine is currently .18ish, but I took a big hit in the past riding it down from .80 to about .50. No doubt I'll make it all back now :)
Awesome looking intraday chart... two steps forward, one step back
.0179 back in the on deck circle
From Forbes.com, Richard Tullis Profile...
Richard H. Tullis
Vice President, Chief Science Officer and Director
Aethlon Medical, Inc.
San Diego , CA
Sector: TECHNOLOGY / Scientific & Technical Instruments
Officer since January 2000
62 Years Old
Dr. Tullis has been Vice President and a director of the Company since January 2000 and Chief Science Officer since June 2001. Dr. Tullis has extensive biotechnology management and research experience, and is the founder of Syngen Research, a wholly-owned subsidiary of Aethlon Medical, Inc. Previously, Dr. Tullis co-founded Molecular Biosystems, Inc., a former NYSE company. At Molecular Biosystems, Dr. Tullis was Director of Oligonucleotide Hybridization, Senior Research Scientist and Member of the Board of Directors. In research, Dr. Tullis developed and patented the first application of oligonucleotides to antisense antibiotics and developed new methods for the chemical synthesis of DNA via methoxy-hosphorochloridites. Dr. Tullis also co-developed the first applications of covalently coupled DNA-enzyme conjugates using synthetic oligonucleotides during his tenure at Molecular Biosystems. In 1985, Dr. Tullis founded, and served as President and CEO of Synthetic Genetics, Inc., a pioneer in custom DNA synthesis, which was sold to Molecular Biology Resources in 1991. Dr. Tullis also served as interim-CEO of Genetic Vectors, Inc., which completed its IPO under his management, and was co-founder of DNA Sciences, Inc., a company that was eventually acquired by Genetic Vectors. Dr. Tullis received his Ph.D. in Biochemistry and Cell Biology from the University of California at San Diego, and has done extensive post-doctoral work at UCSD, USC, and the University of Hawaii.
Compensation for 2008
Salary $172,500.00
Bonus $0.00
Other Annual Compensation $0.00
Long term incentive plan payouts $0.00
Restricted stock awards $0.00
Security underlying options $0.00
All other compensation $0.00
Option awards $ $0.00
Non-equity incentive plan compensation $0.00
Change in pension value and nonqualified deferred compensation earnings $0.00
Total Compensation $172,500.00
Perhaps I should know this, but is this their wholly owned subsidiary?
SynGen Inc.
Private Subsidiary, Headquarters Location
384 Foster City Blvd., Foster City, CA 94404-1105, United States
(650)212-0000, (650)212-0011 fax, http://www.syngendna.com
Primary SIC: Laboratory Analytical Instruments, Primary NAICS: Analytical Laboratory Instrument Manufacturing
Description: Manufacturing: Services: Developer of blood purification technology.
From Aethlon Medical the board of directors list:
"Richard H. Tullis, Ph.D. - Vice President, Chief Science Officer
Dr. Tullis has extensive biotechnology management and research experience, and is the founder of Syngen Research, a wholly-owned subsidiary of Aethlon Medical, Inc. Dr. Tullis became a Vice President and Director of Aethlon Medical, Inc. in January of 2000, and succeeded Dr. Clara M. Ambrus as Chief Scientific Officer in June of 2001. Previously, Dr. Tullis co-founded Molecular Biosystems, Inc., a former NYSE company. At Molecular Biosystems, Dr. Tullis was Director of Research and Development, Director of Oligonucleotide Hybridization, Senior Research Scientist and Member of the Board of Directors. In research, Dr. Tullis developed and patented the first application of oligonucleotides to antisense antibiotics and developed new methods for the chemical synthesis of DNA via methoxy-phosphorochloridites. Dr. Tullis also co-developed the first applications of covalently coupled DNA-enzyme conjugates using synthetic oligonucleotides during his tenure at Molecular Biosystems. In 1985, Dr. Tullis founded, and served as President and CEO of Synthetic Genetics, Inc., a pioneer in custom DNA synthesis, which was sold to Molecular Biology Resources in 1991. Dr. Tullis also served as interim-CEO of Genetic Vectors, Inc., which completed its IPO under his management, and was co-founder of DNA Sciences, Inc., a company that was eventually acquired by Genetic Vectors. Dr Tullis received his Ph.D. in Biochemistry and Cell Biology from the University of California at San Diego, and has done extensive post-doctoral work at UCSD, USC, and The Scripps Research Institute.
"
Nice looking chart, Rocket, thanks - nice to have you back.
I mentioned it.. but only to point out, as you did as well, that it's not even a possibility Sorry to mention the unmentionable.
I may be overly optimistic here, but I can't see how this product doesn't make it eventually... imo ceasing operations isn't an option when they're this close. It's just a matter of time, and once this one starts to get the recognition it deserves, there will be no stopping it. We have a really solid floor here in the mid to low 20's.. I don't think we'll ever see the teens again.
Hey all - just contacted Marc Hill on twitter... said he's 'a few days in'... Looking forward to seeing what he does.
Excellent notes from the Red Chip conference presentation, thanks for sharing!
You share the same excitement for the company's potential as many of us here. Welcome to the board and thanks again :)
Seem as though the 5 am pr's are starting to create a pattern of late day rallies in case there's a PR the next day, and early morning selloffs if there isn't one.
Maybe Paul and Eric should mix it up for the next one.
Nice close all :) See you later tonight.
C'mon scup, slap it for old time's sake!
.021 print
I think people want in before the potential 5 AM PR.... who said E&E wouldn't help?
oops double post sorry
Looks like it could be the right shoulder of the inverted head and shoulders... could see a great EOD..
Inverted head and shoulders forming?
I understand and appreciate all the work you've done... I just think if you organize the list of stores into a more succinct list, one that's more readable and more readily displays the volume of stores (like the PR list or the sales list Rocket made), it will be less cumbersome to read and more effective at communicating your point.. and won't distract the new investors from the posts that precede it or come after. Take it or leave it :)
Thanks again for all the hard work.
Fair enough... Maybe you could condense it in excel for next time and so it's more effective at getting the point across?
Gap seems to be filled?
Scooter, I love you man, but this particular post feels like spam when I'm trying to catch up on 100's of posts, especially when it's posted every day.
We're in thousands of stores, we don't need all of their names, addresses, and numbers. I like the point you're trying to get across, but it's a bit much, IMO... like I said, I think you're great for the board, so no offense... I hope I'm not the only one of this oppinion.. If I am, I'll deal with it :)
Trying to test .023 again already...
We could have that by just after lunchtime if this rate keeps up... of course, it's unlikely, but this is unreal..
wow, about 1M in volume/minute of trading so far...
.022 now... breakout watch... heh
.022 now... breakout watch... heh
'blue skies aabove .023' :D
Morning All!
300+ % in a week and a half IS something ;)
Still expecting a lot more here, though.
Don't expect anyone here to answer your question after that.
Thanks ... didn't see any significance except for the pink elephant that seems to be in the corner of the room.
Can anyone please explain to me, in technical terms, why 'all gaps are eventually filled'?
It might be time to start adding again :)
I'm smelling a PR soon...
Morning Chart. Thanks for all you do for the common man.
Still in ftk here?
I have a WU portfolio to track some of your picks, but I was down big with MPG, got excited about FTK and moved the $ there - 2.35 entry. Waiting patiently this time.
-m2c
You answered your own question...
"yet to be official," "yet to be announced," "potential NA..."
Make any of those things concrete and we fly, imo...
speculation is enough for many Pink players, including many here, but it's not enough for the majority of the non-ihub Whales out there, nor is it enough for those with little discretionary investing capital. All imo
-m2c
Really bullish looking pattern so far today... but what do I know..